Cargando…
Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)
BACKGROUND: Novel and effective immunotherapies are required for refractory or recurrent sarcomas. Transforming growth factor-beta (TGF-β) is a diverse regulatory and fibrogenic protein expressed in multiple sarcoma tumors that promotes epithelial-mesenchymal transition and excessive deposition of e...
Autores principales: | Xie, Lu, Liang, Xin, Xu, Jie, Sun, Xin, Liu, Kuisheng, Sun, Kunkun, Li, Yuan, Tang, Xiaodong, Li, Xianan, Zhan, Xing, Niu, Xiaohui, Guo, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503089/ https://www.ncbi.nlm.nih.gov/pubmed/37715133 http://dx.doi.org/10.1186/s12885-023-11390-4 |
Ejemplares similares
-
Codex Bodley, 2858
Publicado: (1960) -
Générateur déclenche: MPS 2858
por: BaillocL, JM
Publicado: (1967) -
Interpretación del Códice Bodley 2858
por: Caso, Alfonso, 1896-1970
Publicado: (1960) -
A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023) -
Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
por: Zhou, Jun, et al.
Publicado: (2023)